New report predicts both clinical risk and tumor aggressiveness

Interactive report guide

Quickly and easily understand how to interpret the Genomic Prostate Score report.


The Oncotype DX Genomic Prostate Score provides a comprehensive risk profile for personalized information to guide treatment decisions.

Oncotype DX GPS is proven to be an independent predictor of:

Clinical risk

  • Prospectively validated as an independent predictor of both prostate cancer death and metastasis at 10 years1*
  • Predicts future tumor behavior and helps patients understand long-term prognosis to ease patient concerns and offer reassurance1

Tumor aggressiveness

  • Prospectively validated as an independent predictor of adverse pathology2,3†
  • The most important and actionable endpoint when individualizing patient management4,5
  • Identifies patients with less aggressive disease who are likely candidates for Active Surveillance
Start Report Guide
Start Report Guide
Start Report Guide
Start Report Guide
REFERENCES

1. Van Den Eeden et al. AUA 2017. Abstract MP20-05.
2. Klein et al. Eur Urol. 2014.
3. Cullen et al. Eur Urol. 2014.
4. Kozminski et al. Eur Oncol. 2016.
5. Eggener et al. J Urol. 2011.

a. DOI: 10.1016/j.eururo.2017.09.013


* Kaiser Permanente Northern California (KPNC) retrospective cohort study N=279 clinically low, intermediate, and high risk patients; biopsy.
† University of California, San Francisco (UCSF) prospective validation study: N=395 clinically low-risk patients; needle biopsy.
‡ Center for Prostate Disease Research (CPDR) prospective validation study: N=402 clinically low-risk patients; needle biopsy.

Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.